blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2732048

EP2732048 - A NEW CLASSIFIER FOR THE MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.03.2018
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  07.04.2017
FormerGrant of patent is intended
Status updated on  07.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Erasmus University Medical Center Rotterdam
Dr. Molewaterplein 50
3015 GE Rotterdam / NL
[2017/19]
Former [2014/21]For all designated states
Erasmus University Medical Center Rotterdam
Dr. Molewaterplein 50
3015 GE Rotterdam / NL
Inventor(s)01 / KUIPER, Rowan
Pieter de Hoochweg 119a
3024 BG Rotterdam / NL
02 / SONNEVELD, Pieter
Warande 209
3117 CL Schiedam / NL
 [2017/19]
Former [2014/21]01 / KUIPER, Rowan
Pieter de Hoochweg 119a
NL-3024 BG Rotterdam / NL
02 / SONNEVELD, Pieter
Warande 209
NL-3117 CL Schiedam / NL
Representative(s)V.O.
P.O. Box 87930
2508 DH Den Haag / NL
[2017/19]
Former [2014/21]Habets, Winand
Life Science Patents
PO Box 5096
6130 PB Sittard / NL
Application number, filing date12733765.712.07.2012
[2017/19]
WO2012EP63722
Priority number, dateEP2011017397114.07.2011         Original published format: EP 11173971
[2014/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013007795
Date:17.01.2013
Language:EN
[2013/03]
Type: A1 Application with search report 
No.:EP2732048
Date:21.05.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 17.01.2013 takes the place of the publication of the European patent application.
[2014/21]
Type: B1 Patent specification 
No.:EP2732048
Date:10.05.2017
Language:EN
[2017/19]
Search report(s)International search report - published on:EP17.01.2013
ClassificationIPC:C12Q1/68
[2014/21]
CPC:
C12Q1/6886 (EP,EA,US); C12Q1/6813 (KR); C12Q1/6837 (EP,EA,US);
C12Q2600/112 (EP,EA,US); C12Q2600/118 (EP,EA,US); C12Q2600/158 (EP,EA,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/21]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NEUE EINSTUFUNG ZUR MOLEKULAREN EINSTUFUNG VON MEHRFACHEN MYELOMEN[2017/08]
English:A NEW CLASSIFIER FOR THE MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA[2014/21]
French:NOUVEAU CLASSIFICATEUR POUR LA CLASSIFICATION MOLÉCULAIRE DU MYÉLOME MULTIPLE[2014/21]
Former [2014/21]NEUER KLASSIFIKATOR ZUR MOLEKULAREN KLASSIFIZIERUNG VON MULTIPLEM MYELOM
Entry into regional phase14.01.2014National basic fee paid 
14.01.2014Designation fee(s) paid 
14.01.2014Examination fee paid 
Examination procedure14.01.2014Amendment by applicant (claims and/or description)
14.01.2014Examination requested  [2014/21]
05.12.2014Despatch of a communication from the examining division (Time limit: M04)
26.03.2015Reply to a communication from the examining division
09.03.2016Despatch of a communication from the examining division (Time limit: M02)
17.03.2016Reply to a communication from the examining division
08.02.2017Communication of intention to grant the patent
29.03.2017Fee for grant paid
29.03.2017Fee for publishing/printing paid
29.03.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.12.2014
Opposition(s)13.02.2018No opposition filed within time limit [2018/16]
Fees paidRenewal fee
28.07.2014Renewal fee patent year 03
27.07.2015Renewal fee patent year 04
30.06.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.07.2012
AL10.05.2017
CY10.05.2017
CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
MC10.05.2017
MK10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
MT12.07.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
[2020/34]
Former [2019/51]HU12.07.2012
CY10.05.2017
CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
MC10.05.2017
MK10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
MT12.07.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2019/46]HU12.07.2012
CY10.05.2017
CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
MC10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
MT12.07.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2019/31]HU12.07.2012
CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
MC10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
MT12.07.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2019/30]CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
MC10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
MT12.07.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2018/43]CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
MT12.07.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2018/25]CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
RO10.05.2017
RS10.05.2017
SI10.05.2017
SK10.05.2017
SM10.05.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2018/11]CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
RO10.05.2017
RS10.05.2017
SK10.05.2017
SM10.05.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2018/10]CZ10.05.2017
EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
RO10.05.2017
RS10.05.2017
SK10.05.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2018/09]EE10.05.2017
HR10.05.2017
LT10.05.2017
LV10.05.2017
RS10.05.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2017/50]HR10.05.2017
LT10.05.2017
LV10.05.2017
RS10.05.2017
BG10.08.2017
GR11.08.2017
IS10.09.2017
Former [2017/49]HR10.05.2017
LT10.05.2017
GR11.08.2017
IS10.09.2017
Cited inInternational search[AD]   DECAUX OLIVIER ET AL: "Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Mylome.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 29, 10 October 2008 (2008-10-10), pages 4798 - 4805, XP002667014, ISSN: 1527-7755 [AD] 1-5 * abstract * * page 4799, column 1; figure 3 *

DOI:   http://dx.doi.org/10.1200/jco.2007.13.8545
Examination  W J CHNG ET AL: "Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature", LEUKEMIA, vol. 22, no. 2, 1 February 2008 (2008-02-01), pages 459 - 461, XP055156208, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2404934

DOI:   http://dx.doi.org/10.1038/sj.leu.2404934
by applicant  KUIPER, R. ET AL., LEUKEMIA, 2012, pages 1 - 8 [AD] 1-5 * abstract * * page 4799, column 1; figure 3 *
   GREIPP PR; SAN MIGUEL J; DURIE BG; CROWLEY JJ; BARLOGIE B; BLADE J ET AL.: "International staging system for multiple myeloma", J CLIN ONCOL., vol. 23, no. 15, 20 May 2005 (2005-05-20), pages 3412 - 20
   BERGSAGEL PL; KUEHL WM.: "Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma", J CLIN ONCOL., vol. 23, no. 26, 10 September 2005 (2005-09-10), pages 6333 - 8
   FONSECA R; DEBES-MARUN CS; PICKEN EB; DEWALD GW; BRYANT SC; WINKLER JM ET AL.: "The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma", BLOOD, vol. 102, no. 7, 1 October 2003 (2003-10-01), pages 2562 - 7
   FONSECA R; HOYER JD; AGUAYO P; JALAL SM; AHMANN GJ; RAJKUMAR SV ET AL.: "Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma", LEUK LYMPHOMA, vol. 35, no. 5-6, 1999, pages 599 - 60
   KEATS JJ; REIMAN T; MAXWELL CA; TAYLOR BJ; LARRATT LM; MANT MJ ET AL.: "In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression", BLOOD, vol. 101, no. 4, 15 February 2003 (2003-02-15), pages 1520 - 9
   AVET-LOISEAU H; MALARD F; CAMPION L; MAGRANGEAS F; SEBBAN C; LIOURE B ET AL.: "Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?", BLOOD, vol. 117, no. 6, 10 February 2011 (2011-02-10), pages 2009 - 11
   CREMER FW; BILA J; BUCK , KARTAL M; HOSE D; ITTRICH C ET AL.: "Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics", GENES, CHROMOSOMES & CANCER, vol. 44, no. 2, October 2005 (2005-10-01), pages 194 - 203
   ZHAN F; HUANG Y; COLLA S; STEWART JP; HANAMURA , GUPTA S ET AL.: "The molecular classification of multiple myeloma", BLOOD, vol. 108, no. 6, 15 September 2006 (2006-09-15), pages 2020 - 8
   BROYL A; HOSE D; LOKHORST H; DE KNEGT Y; PEETERS J; JAUCH A ET AL.: "Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients", BLOOD, vol. 116, no. 14, 7 October 2010 (2010-10-07), pages 2543 - 53
   CHNG WJ; KUEHL WM; BERGSAGEL PL; FONSECA R: "Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature", LEUKEMIA, vol. 22, no. 2, February 2008 (2008-02-01), pages 459 - 61
   SHAUGHNESSY JD, JR.; ZHAN F; BURINGTON BE; HUANG Y; COLLA S, HANAMURA ET AL.: "A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1", BLOOD, vol. 109, no. 6, 15 March 2007 (2007-03-15), pages 2276 - 84
   MULLIGAN G; MITSIADES C; BRYANT B; ZHAN F; CHNG WJ; ROELS S ET AL.: "Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib", BLOOD, vol. 109, no. 8, 15 April 2007 (2007-04-15), pages 3177 - 88
   DECAUX O; LODE L; MAGRANGEAS F; CHARBONNEL C; GOURAUD W; JEZEQUEL P ET AL.: "Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome", J CLIN ONCOL., vol. 26, no. 29, 10 October 2008 (2008-10-10), pages 4798 - 805
   DICKENS NJ; WALKER BA; LEONE PE; JOHNSON DC; BRITO JL; ZEISIG A ET AL.: "Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome", CLIN CANCER RES., vol. 16, no. 6, 15 March 2010 (2010-03-15), pages 1856 - 64
   HOSE D; REME T; HIELSCHER T; MOREAUX J; MESSNER T; SECKINGER A ET AL.: "Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma", HAEMATOLOGICA, vol. 96, no. 1, January 2011 (2011-01-01), pages 87 - 95
   SONNEVELD P; SCHMIDT-WOLF I; VAN DER HOLT B; JARARI LE; BERTSCH U; SALWENDER H ET AL.: "HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM", BLOOD, vol. 116, no. 21, 19 November 2010 (2010-11-19), pages 40
   BARLOGIE B; PINEDA-ROMAN M; VAN RHEE F; HAESSLER J; ANAISSIE E; HOLLMIG K ET AL.: "Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities", BLOOD, vol. 112, no. 8, 15 October 2008 (2008-10-15), pages 3115 - 21
   PINEDA-ROMAN M; ZANGARI M; HAESSLER J; ANAISSIE E; TRICOT G; VAN RHEE F ET AL.: "Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2", BRITISH JOURNAL OF HAEMATOLOGY, vol. 140, no. 6, March 2008 (2008-03-01), pages 625 - 34
   MORGAN GJ; DAVIES FE; GREGORY WM; BELL SE; SZUBERT AJ; NAVARRO-COY N ET AL.: "Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results", BLOOD, vol. 116, no. 21, 19 November 2010 (2010-11-19), pages 623
   MORGAN GJ; DAVIES FE; OWEN RG; RAWSTRON AC; BELL S; COCKS K ET AL.: "Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study", BLOOD, vol. 110, no. 11, 16 November 2007 (2007-11-16), pages 3593
   JAGANNATH S; BARLOGIE B; BERENSON J; SIEGEL D; IRWIN D; RICHARDSON PG ET AL.: "A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma", BRITISH JOURNAL OF HAEMATOLOGY, vol. 127, no. 2, October 2004 (2004-10-01), pages 165 - 72
   RICHARDSON PG; BARLOGIE B; BERENSON J; SINGHAL S; JAGANNATH S; IRWIN D ET AL.: "A phase 2 study of bortezomib in relapsed, refractory myeloma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 348, no. 26, 26 June 2003 (2003-06-26), pages 2609 - 17
   RICHARDSON PG; SONNEVELD P; SCHUSTER MW; IRWIN D; STADTMAUER EA; FACON T ET AL.: "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 352, no. 24, 16 June 2005 (2005-06-16), pages 2487 - 98
   BAIR E; HASTIE T; PAUL D; TIBSHIRANI R.: "Prediction by Supervised Principal Components", J AMER STATISTICAL ASSOC., vol. 101, no. 473, 1 March 2006 (2006-03-01), pages 119 - 37
   AVET-LOISEAU H; MAGRANGEAS F; MOREAU P; ATTAL M; FACON T; ANDERSON K ET AL.: "Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications", J CLIN ONCOL., vol. 29, no. 14, 10 May 2011 (2011-05-10), pages 1893 - 7
   AVET-LOISEAU H; ATTAL M; MOREAU P; CHARBONNEL C; GARBAN F; HULIN C ET AL.: "Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome", BLOOD, vol. 109, no. 8, 15 April 2007 (2007-04-15), pages 3489 - 95
   FONSECA R; BERGSAGEL PL; DRACH J; SHAUGHNESSY J; GUTIERREZ N; STEWART AK ET AL.: "International Myeloma Working Group molecular classification of multiple myeloma: spotlight review", LEUKEMIA, vol. 23, no. 12, December 2009 (2009-12-01), pages 2210 - 21
   AVET-LOISEAU H; LELEU X; ROUSSEL M; MOREAU P; GUERIN-CHARBONNEL C; CAILLOT D ET AL.: "Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p", J CLIN ONCOL., vol. 28, no. 30, 20 October 2010 (2010-10-20), pages 4630 - 4
   NEBEN K; JAUCH A; BERTSCH U; HEISS C; HIELSCHER T; SECKINGER A ET AL.: "Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation", HAEMATOLOGICA, vol. 95, no. 7, July 2010 (2010-07-01), pages 1150 - 7
   CARRASCO DR; TONON G; HUANG Y; ZHANG Y; SINHA R; FENG B ET AL.: "High- resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients", CANCER CELL., vol. 9, no. 4, 2006, pages 313 - 25
   KUIPER, R. ET AL., LEUKEMIA, 22 June 2012 (2012-06-22), pages 1 - 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.